CASSAVA SCIENCES INC (SAVA)       33.62  -0.12 (-0.36%)

33.62  -0.12 (-0.36%)

US14817C1071 - Common Stock - After market: 33.91 +0.29 (+0.86%)

CASSAVA SCIENCES INC33.62

NASDAQ:SAVA (12/6/2022, 7:02:17 PM)-0.12 (-0.36%)

After market: 33.91 +0.29 (+0.86%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Pharmaceuticals
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-07 2022-11-07/bmo Earnings (Next) 02-27 2023-02-27
Ins Owners 4.57% Inst Owners 25.22%
Market Cap 1.40B Shares 41.74M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 76
IPO 07-14 2000-07-14

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

SAVA Daily chart

Company Profile

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. The company is headquartered in Austin, Texas and currently employs 24 full-time employees. The company went IPO on 2000-07-14. The firm is primarily focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimer's disease. The firm develops pharmaceutical product candidates that offer improvements to patients and healthcare professionals. The Company’s products include Simufilam and SavaDx. Its lead therapeutic product candidate, Simufilam, is a small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. The firm is conducting a Phase III program with Simufilam in patients with mild-to-moderate Alzheimer’s disease dementia. Its investigational product candidate, SavaDx, is an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood. SavaDx is designed as an antibody-based detection system for altered filamin A (FLNA).

Company Info

CASSAVA SCIENCES INC

6801 N Capital Of Texas Highway, Building 1; Suite 300

Austin TEXAS 78731

P: 15125012444.0

CEO: Remi Barbier

Employees: 24

Website: https://www.cassavasciences.com/company

SAVA News

News Image13 hours ago - Market News VideoNoteworthy Tuesday Option Activity: SAVA, NRG, SINews Image19 hours ago - Cassava Sciences, Inc.Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease

Outside Biostatisticians with Specific Expertise in Alzheimer’s Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical...

News Image19 hours ago - Cassava Sciences, Inc.Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s DiseaseNews Image9 days ago - Market News VideoNoteworthy Monday Option Activity: QCOM, SAVA, MBINews Image15 days ago - Cassava Sciences, Inc.Cassava Sciences Announces Closing of $50 Million Registered Direct Offering

AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage...

News Image15 days ago - Cassava Sciences, Inc.Cassava Sciences Announces Closing of $50 Million Registered Direct Offering

SAVA Twits

Here you can normally see the latest stock twits on SAVA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example